Alumis (ALMS) stock gains as Oppenheimer initiates coverage with an Outperform recommendation, citing a valuation disconnect. Read more here.

B. Riley initiates Foghorn Therapeutics at buy with $10 price target, citing promising development of SMARCA2 inhibitors for ...